Sensible Medical Innovations Overview
Sensible Medical Innovations has developed the ReDS medical radar technology, which originated from the defense industrys see through walls technology. ReDS is designed to monitor and manage patients with fluid management problems, including patients living with heart failure (HF), taking diuretic medication, or recovering from an event related to coronary artery disease. ReDS is intended for use by qualified healthcare practitioners and by patients under the direction of a physician in hospitals, hospital-type facilities, and the home environment. In a pilot study, ReDS-guided HF management reduced the number of HF-related rehospitalizations by approximately 80%. The company is headquartered in Israel with commercial offices in the United States. In August 2015, Sensible Medicals noninvasive thoracic fluid status monitor was cleared for market in the United States.
Cumulative Funding Raised Over Time ($)
$10.0MJan 2019
$17.0MJun 2009
$37.0MNov 2013
Latest News
growth-positive
/PRNewswire/ -- Sensible Medical today announced that its ReDS™ Pro System has been contracted for inclusion in the Federal Supply Schedule (FSS), making it...
Sensible Medical has announced that its ReDS™ Pro System has been included in the Federal Supply Schedule (FSS), facilitating its purchase by VA Medical Centers and other federal healthcare facilities across the U.S. The ReDS™ Pro System is a non-invasive device designed to measure lung fluid volume, aiding clinicians in managing heart failure and other conditions. With FSS approval, VA facilities can procure the system under pre-negotiated terms, enhancing access for veterans. The ReDS System is applicable in various care settings and has FDA 510(k) clearance and a CE mark. Sensible Medical aims to improve heart failure patient care through innovative solutions.
Product StageCustomers
growth-positive
Sensible Medical Sold Covid-19 Patient Monitoring Systems to Hospitals in Italy, U.S., Says CEO
Sensible Medical Innovation Ltd., an Israel-based medtech company, has developed a radar-based system that can continuously monitor lung fluid levels in coronavirus patients. The system offers real-time insights on any deterioration in the patients status, providing vital information for immediate care. The radar technology used by the system can be used through clothes and for long periods of time, unlike a CT scan. Four hospitals in Italy have already acquired the system, with a U.S. hospital purchasing 20 units. Sensible Medical counts Boston Scientific Corp., Shanghai Longtech Precision Machinery Co. Ltd., and Genesis Partners among its backers.
CustomersPartners
growth-positive
Sensible Medical Innovations Licenses ReDS™ Technology to Bayer
Sensible Medical Innovations and Bayer have signed an agreement, making Bayer Sensibles largest customer in Europe. Bayer will use Sensible ReDS™ technology as a biomarker to monitor lung congestion in a clinical trial. Sensibles ReDS System is a wearable vest that quantifies lung fluid non-invasively. The technology is primarily being commercialized in the US, but this agreement is a major step forward in the European market. Sensible Medical Innovations aims to develop a new standard of care in lung fluid management.
Customers
growth-positive
Medicure invests $10M Sensible Medical to market ReDS
The Indian Bio & Health Sciences Industry awards, known as the BioSpectrum Excellence Awards, were held on June 30, 2023. The awards honor the achievements of industry leaders in the Indian Bio & Health Sciences Industry. The event is highly anticipated in the industry.
None
growth-positive
Ohio State Studies If High-tech Vest Can Help Manage Heart Failure at Home
Doctors at The Ohio State University Richard M. Ross Heart Hospital are testing a high-tech vest that measures fluid inside the lungs to prevent repeated hospital trips for heart failure patients. The SensiVest, created by Sensible Medical, uses radar technology to accurately measure water inside the lungs. The vest is being tested in a national clinical trial to determine its effectiveness in monitoring and managing lung fluid, reducing hospitalizations, and improving quality of life. A previous study showed an 87 percent reduction in heart failure hospitalizations with the use of the vest. Patients in the trial will be followed for up to nine months.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $37.56M |
| Last funding | $61K |
| Stage | Mature |
| Rounds | 5 |
| Investors | 4 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | sensible-medical.com |
| Careers | Careers page |
Locations
Meir Ariel St 6, Netanya, Israel
64 North Summit Street, Tenafly, New Jersey, USA
Photos & Videos
3 item(s)
Sensible Medical Innovations Business
Business models
B2B2C, B2B, B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcarePatient Remote MonitoringTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Semiconductors & ElectronicsWearablesSensingCommunicationsRadio FrequencyIOTSimulation & ImagingTags (17)
cardiologyiotnon-invasivepulmonarymonitoringdigital-healthcaresensorswearablehealthcare-providershospitalsdoctorsclinicsremote-monitoringhome-careimagingdecision-supportrf-technologyGeographic Markets
EuropeUnited StatesSensible Medical Innovations Financials
$37.56M
Total funding
Undisclosed
Capital raised
$61K
Last funding
Mature
Funding stage
5
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$10.0MJan 2019
$17.0MJun 2009
$37.0MNov 2013
Private Equity Funding
Undisclosed Round
Jan 2019
$10M
Medicure Inc.
B Round
Nov 2013
$20M
Genesis Partners, SCP Vitalife
A Round
Jun 2009
$7M
Vitalife, Genesis Partners
Non-Equity Funding
GrantEvent
Sep 2019
$61K
EU Horizon 2020
GrantEvent
May 2009
$500K
Cleveland Clinic
Sensible Medical Innovations Lifecycle
Cumulative Funding Raised Over Time
$10.0MJan 2019
$17.0MJun 2009
$37.0MNov 2013
All Events
Undisclosed Round
Jan 2019
$10M
Medicure Inc.
B Round
Nov 2013
$20M
Genesis Partners, SCP Vitalife
A Round
Jun 2009
$7M
Vitalife, Genesis Partners
GrantEvent
Sep 2019
$61K
EU Horizon 2020
GrantEvent
May 2009
$500K
Cleveland Clinic
Sensible Medical Innovations News
9 articles
growth-positive
/PRNewswire/ -- Sensible Medical today announced that its ReDS™ Pro System has been contracted for inclusion in the Federal Supply Schedule (FSS), making it...
Sensible Medical has announced that its ReDS™ Pro System has been included in the Federal Supply Schedule (FSS), facilitating its purchase by VA Medical Centers and other federal healthcare facilities across the U.S. The ReDS™ Pro System is a non-invasive device designed to measure lung fluid volume, aiding clinicians in managing heart failure and other conditions. With FSS approval, VA facilities can procure the system under pre-negotiated terms, enhancing access for veterans. The ReDS System is applicable in various care settings and has FDA 510(k) clearance and a CE mark. Sensible Medical aims to improve heart failure patient care through innovative solutions.
Product StageCustomers
growth-positive
Sensible Medical Sold Covid-19 Patient Monitoring Systems to Hospitals in Italy, U.S., Says CEO
Sensible Medical Innovation Ltd., an Israel-based medtech company, has developed a radar-based system that can continuously monitor lung fluid levels in coronavirus patients. The system offers real-time insights on any deterioration in the patients status, providing vital information for immediate care. The radar technology used by the system can be used through clothes and for long periods of time, unlike a CT scan. Four hospitals in Italy have already acquired the system, with a U.S. hospital purchasing 20 units. Sensible Medical counts Boston Scientific Corp., Shanghai Longtech Precision Machinery Co. Ltd., and Genesis Partners among its backers.
CustomersPartners
growth-positive
Sensible Medical Innovations Licenses ReDS™ Technology to Bayer
Sensible Medical Innovations and Bayer have signed an agreement, making Bayer Sensibles largest customer in Europe. Bayer will use Sensible ReDS™ technology as a biomarker to monitor lung congestion in a clinical trial. Sensibles ReDS System is a wearable vest that quantifies lung fluid non-invasively. The technology is primarily being commercialized in the US, but this agreement is a major step forward in the European market. Sensible Medical Innovations aims to develop a new standard of care in lung fluid management.
Customers
growth-positive
Medicure invests $10M Sensible Medical to market ReDS
The Indian Bio & Health Sciences Industry awards, known as the BioSpectrum Excellence Awards, were held on June 30, 2023. The awards honor the achievements of industry leaders in the Indian Bio & Health Sciences Industry. The event is highly anticipated in the industry.
None
growth-positive
Ohio State Studies If High-tech Vest Can Help Manage Heart Failure at Home
Doctors at The Ohio State University Richard M. Ross Heart Hospital are testing a high-tech vest that measures fluid inside the lungs to prevent repeated hospital trips for heart failure patients. The SensiVest, created by Sensible Medical, uses radar technology to accurately measure water inside the lungs. The vest is being tested in a national clinical trial to determine its effectiveness in monitoring and managing lung fluid, reducing hospitalizations, and improving quality of life. A previous study showed an 87 percent reduction in heart failure hospitalizations with the use of the vest. Patients in the trial will be followed for up to nine months.
Customers
Groundbreaking Use of Radar-Equipped Vests in a Hospital Promises to Improve the Care of Heart Failure Patients
growth-positive
Sensible Medical Innovations Receives FDA 510K Clearance for its Non-Invasive Thoracic Fluid Status Monitor
Sensible Medical Innovations has received clearance from the FDA for its non-invasive thoracic fluid status monitor. The product, powered by ReDS medical radar technology, allows patients to measure their lung fluid content at home and upload the results to a secure cloud application for healthcare professionals to review. This technology aims to improve the quality of life for patients with fluid management problems and reduce hospital readmissions. Sensible Medical Innovations is excited to enter the US market with this solution.
Customers
growth-positive
Sensible Medical Innovations Ltd. opening first U.S. office in Columbus, Ohio
Sensible Medical Innovations, an Israeli company developing a non-invasive device for monitoring congestive heart failure patients, is opening its first U.S. office. The company received a $7 million investment from venture firms SPC Vitalife and Genesis Partners. Sensible Medical aims to replace exploratory surgery with its imaging device, which has been tested in animals and is preparing for human trials. The company plans to work with Ohio State University and the Cleveland Clinic for testing and expects to hire more employees in Ohio.
InvestmentExpand
growth-positive
Israeli CHF company Sensible Medical Innovations raises $7m
Israeli company Sensible Medical Innovations has raised $7 million in a fund raising round led by Genesis and Vitalife funds. The company is developing a non-invasive device for monitoring congestive heart failure and has developed an imaging method for internal organs based on IT technology. Sensible Medicals product has been successfully tested on animals and will now go forward to human trials.
Investment
Sensible Medical Innovations Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 36 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Sensible Medical Innovations Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514046226 |
| Crunchbase | sensible-medical-innovations |
| Phone | +97298654402 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Orli Wollner |
| Updater email | orlushka@gmail.com |
| Last update | 2021-01-26T00:00:00.000Z |
| Created | 2014-06-25T00:00:00.000Z |